Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microemulsion DNK333 in atopic dermatitis – antipruritic efficacy and exposure study
2009-012098-36Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of DNK333 in atopic dermatitis (AD) and pruritus (6 arms), sponsored by Novartis. Primary endpoints: Average nocturnal activity intensity per hour (actigraphy) and Pruritus intensity (Visual Analog Scale). Started Jul 2009; status: completed.
02
Drugs
DNK333
03
Conditions
atopic dermatitis (AD)pruritus
Beyond the preview
Go deeper on 2009-012098-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012098-36.